查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930090

全球镥-177市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Lutetium-177 Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

镥-177 (Lu-177) 市场成长因素

由于标靶放射性核种疗法在肿瘤学领域的应用日益广泛，全球镥-177 (Lu-177) 市场正经历快速成长。 根据 Fortune Business Insights 预测，镥-177 市场规模预计在 2025 年达到 27.3 亿美元，并在 2026 年达到 34.3 亿美元。预计到 2034 年，该市场规模将达到 147 亿美元，2026 年至 2034 年的复合年增长率高达 19.95%。

北美地区凭藉较高的癌症发生率、完善的医保报销系统以及大型镥-177 生产设施，在全球镥-177 市场占主导地位，预计到 2025 年将占 80.95% 的市场占有率。

市场概览

镥-177 是一种放射性同位素，广泛用于标靶放射性核素治疗，特别适用于治疗摄护腺癌和神经内分泌肿瘤。 透过与前列腺特异性膜抗原 (PSMA) 等特定受体结合，镥-177 可将 β 射线直接输送至癌细胞，从而最大限度地减少对周围健康组织的损伤。这些临床优势使镥-177 成为精准肿瘤治疗的关键组成部分。

全球癌症发生率上升、对标靶治疗的需求不断增长以及主要製药公司强大的研发管线正在推动市场成长。诺华製药、兰特斯控股和泰利克斯製药等领先企业正积极投资临床试验和产品拓展。

市场驱动因素

癌症发生率上升

癌症发生率的上升，尤其是前列腺癌和神经内分泌肿瘤的发生率上升，是镥-177 市场的主要驱动因素。 基于 Lu-177 的疗法提高了治疗的精准度，使其非常适合晚期和转移性癌症。

例如，根据美国癌症协会估计，到 2025 年，美国将新增 313,780 例前列腺癌病例，随着需要标靶治疗的患者群体不断扩大，这无疑将推动市场成长。

积极的研发活动

广泛的研发活动和后期临床试验正在进一步加速市场成长。 2023 年 12 月，Lantheus Holdings 与 Point BioPharma 合作，宣布了针对转移性去势抵抗性前列腺癌的 177Lu-PNT2002 的 III 期 SPLASH 试验的积极顶线结果，进一步增强了人们对基于 Lu-177 疗法的信心。

市场限制因子

儘管成长前景强劲，但钌-177疗法的高昂成本仍然是一个挑战，尤其是在中低收入国家。放射性药物生产、专用设施、监管合规和培训人员等相关费用显着增加了治疗成本。

此外，发展中地区核医基础设施的匮乏和不完善的报销政策阻碍了该疗法的广泛应用。

市场机会

临床适应症的拓展

越来越多的临床试验正在探索钌-177的新治疗适应症，这带来了巨大的成长机会。 新型钌-177候选药物及其儿科适应症的监管审批正在扩大目标患者群体。

例如，美国食品药物管理局 (FDA) 授予 Y-mAbs Therapeutics 公司的 177Lu-omburtamab-DTPA 治疗罕见儿科疾病的资格认定，凸显了其在成人肿瘤学以外的未来成长潜力。

市场趋势

联合疗法的成长

将钌-177 与化疗和免疫疗法合併应用正成为主要趋势。联合疗法可以提高疗效、降低抗药性并最大限度地减少辐射剂量。製药公司在合作开发此类疗法方面正获得越来越多的进展。

细分市场分析

依药物类型

市场依药物类型细分：Lutathera、Pluvicto 和其他。

2024年，由于神经内分泌肿瘤发生率的上升，Lutathera（铠-177）占了市场主导地位。 Pravict预计将强劲成长，这得益于前列腺癌病例的增加以及健保报销的批准，包括加拿大于2025年3月正式批准其医疗保险报销。

依年龄组别划分

2024年，成人市场占主导地位，这主要得益于65岁以上人口前列腺癌的高发生率。由于Lu-177疗法获准用于儿童，预计儿童市场将保持稳定成长。

依应用领域划分

2024年，摄护腺癌领域占了最大的市场占有率，这主要得益于疾病发生率的上升和新产品的上市。 由于发病率上升和持续的研发活动，神经内分泌肿瘤领域预计也将显着成长。

依最终使用者划分

截至2024年，医院凭藉其先进的放射性药物基础设施和与生物技术公司加强的合作，引领市场。专科诊所和研究机构的应用也不断扩展。

区域洞察

在先进的医疗基础设施和强有力的报销政策的推动下，北美镥-177市场在2025年的价值将达到22.1亿美元。由于主要製造商和生产设施的所在地，美国仍然是最大的贡献者。

由于癌症病例数的增加和专业核医中心的扩张，欧洲占第二大市场。由于癌症发生率上升、临床试验的扩展以及对放射性药物研究投资的增加，亚太地区预计将成为成长最快的地区。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家/地区主要疾病流行情形（2025 年）
  • 主要公司产品线分析
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作等）
  • 新冠疫情对市场的影响

第五章 全球镥-177 市场分析：洞察与预测 (2021-2034)

  • 市场分析、洞察与预测：依药物分类
    • Lutathera（镥-177 氧曲肽）
    • Pruvikt（镥-177 比匹博肽四氢西坦）
    • 其他
  • 市场分析、洞察与预测：依年龄组别分类
    • 成人
    • 儿童
  • 市场分析、洞察与预测：依应用分类
    • 神经内分泌肿瘤
    • 摄护腺癌
    • 其他
  • 市场分析、洞察与预测：依最终用户分类
    • 医院
    • 专科诊所
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区 (ROW)

第六章：北美铠-177市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲镥-177市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 德国
    • 美国王国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 其他欧洲国家

第八章 亚太地区镥-177市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 世界其他地区（ROW）镥-177市场分析：洞察与预测（2021-2034）

第十章 竞争分析

  • 全球市占率分析（2025）
  • 公司型材
    • Novartis AG
    • Telix Pharmaceuticals Limited
    • Ariceum Therapeutics
    • Radiopharm Theranostics Limited
    • Lantheus Holdings, Inc.
    • Y-mAbs Therapeutics, Inc.
    • GLYTHERIX
    • Curium
Product Code: FBI112740

Growth Factors of lutetium-177 (Lu-177) Market

The global lutetium-177 (Lu-177) market is witnessing rapid expansion due to the growing adoption of targeted radionuclide therapies in oncology. According to Fortune Business Insights, the lutetium-177 market size was valued at USD 2.73 billion in 2025 and is projected to grow to USD 3.43 billion in 2026. The market is expected to reach USD 14.7 billion by 2034, registering a strong CAGR of 19.95% during the 2026-2034 forecast period.

North America dominated the global lutetium-177 market with an 80.95% market share in 2025, driven by high cancer prevalence, robust reimbursement frameworks, and the presence of large-scale Lu-177 production facilities.

Market Overview

Lutetium-177 is a radioactive isotope widely used in targeted radionuclide therapy, particularly for treating prostate cancer and neuroendocrine tumors. It delivers beta radiation directly to cancer cells by binding to specific receptors such as prostate-specific membrane antigen (PSMA), thereby minimizing damage to surrounding healthy tissues. These clinical advantages have positioned Lu-177 as a critical component of precision oncology.

The rising incidence of cancer globally, increasing demand for targeted treatments, and strong research and development pipelines from leading pharmaceutical companies are accelerating market growth. Prominent players such as Novartis AG, Lantheus Holdings, Inc., and Telix Pharmaceuticals Limited are actively investing in clinical trials and product expansion.

Market Drivers

Rising Prevalence of Cancer

The increasing burden of cancer, particularly prostate cancer and neuroendocrine tumors, is a primary driver of the lutetium-177 market. Lu-177-based therapies offer improved therapeutic precision, making them highly suitable for advanced and metastatic cancers.

For instance, according to the American Cancer Society, 313,780 new prostate cancer cases were estimated in the U.S. in 2025, highlighting the growing patient pool requiring targeted therapies and supporting market expansion.

Strong Research and Development Activity

Extensive R&D efforts and late-stage clinical trials are further propelling market growth. In December 2023, Lantheus Holdings, Inc., in collaboration with POINT Biopharma, announced positive topline results from the Phase 3 SPLASH study evaluating 177Lu-PNT2002 for metastatic castration-resistant prostate cancer, reinforcing confidence in Lu-177-based treatments.

Market Restraints

Despite strong growth prospects, the market faces challenges due to the high cost of Lu-177 treatment, particularly in lower- and middle-income countries. Costs associated with radiopharmaceutical manufacturing, specialized facilities, regulatory compliance, and trained personnel significantly increase treatment expenses.

Additionally, limited nuclear medicine infrastructure and inadequate reimbursement policies in developing regions restrict widespread adoption.

Market Opportunities

Expansion of Clinical Applications

The increasing number of clinical trials exploring new therapeutic indications for Lu-177 presents significant growth opportunities. Regulatory approvals for new Lu-177 candidates and pediatric indications are expanding the addressable patient population.

For example, the U.S. FDA granted Rare Pediatric Disease Designation to Y-mAbs Therapeutics for 177Lu-omburtamab-DTPA, highlighting future growth potential beyond adult oncology.

Market Trends

Growth of Combination Therapies

The use of Lu-177 in combination with chemotherapy and immunotherapy is emerging as a key trend. Combination approaches enhance treatment efficacy, reduce resistance, and allow lower radiation doses. Pharmaceutical collaborations aimed at developing such therapies are gaining momentum.

Segmentation Analysis

By Drug

Based on drug type, the market is segmented into LUTATHERA, PLUVICTO, and others.

LUTATHERA (lutetium Lu 177 dotatate) held a dominant share in 2024 due to rising neuroendocrine tumor prevalence. PLUVICTO is expected to witness strong growth, supported by increasing prostate cancer cases and reimbursement approvals, such as Canada's public reimbursement decision in March 2025.

By Age Group

The adult segment dominated the market in 2024, driven by the high prevalence of prostate cancer among individuals aged 65 and above. The pediatric segment is expected to grow steadily due to regulatory approvals for pediatric use of Lu-177 therapies.

By Application

The prostate cancer segment accounted for the largest share in 2024, supported by increasing disease prevalence and product launches. The neuroendocrine tumors segment is also expected to grow notably due to rising incidence and ongoing R&D activities.

By End User

Hospitals dominated the market in 2024, owing to advanced infrastructure for handling radiopharmaceuticals and increasing collaborations with biotechnology companies. Specialty clinics and research institutes are also witnessing growing adoption.

Regional Insights

The North America lutetium-177 market was valued at USD 2.21 billion in 2025, driven by advanced healthcare infrastructure and strong reimbursement policies. The U.S. remains the largest contributor due to the presence of major manufacturers and production facilities.

Europe holds the second-largest share, supported by rising cancer cases and dedicated nuclear medicine centers. Asia Pacific is projected to be the fastest-growing region due to increasing cancer prevalence, expanding clinical trials, and growing investment in radiopharmaceutical research.

Competitive Landscape

The market is consolidated, with Novartis AG holding a significant share due to its robust product portfolio and regulatory approvals. Other key players include Telix Pharmaceuticals, Lantheus Holdings, Radiopharm Theranostics, and Curium, all actively expanding their Lu-177 pipelines.

Conclusion

The global lutetium-177 market, valued at USD 2.73 billion in 2025, is projected to grow to USD 3.43 billion in 2026 and reach USD 14.7 billion by 2034. The increasing prevalence of cancer, strong clinical pipelines, and rising adoption of targeted radionuclide therapy are expected to support sustained market growth over the forecast period.

Segmentation By Drug

  • LUTATHERA (lutetium Lu 177 dotatate)
  • PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
  • Others

By Age Group

  • Adults
  • Pediatrics

By Application

  • Neuroendocrine Tumor
  • Prostate Cancer
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America (By Drug, Age Group, Application, End-User, and Country)
    • U.S.
    • Canada
  • Europe ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World ( By Drug, Age Group, Application, and End-User)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. New Product Launches, by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 5.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Adults
    • 5.2.2. Pediatrics
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Neuroendocrine Tumors
    • 5.3.2. Prostate Cancer
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By End-User
    • 5.4.1. Hospitals
    • 5.4.2. Specialty Clinics
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of the World

6. North America Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 6.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Adults
    • 6.2.2. Pediatrics
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Neuroendocrine Tumors
    • 6.3.2. Prostate Cancer
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By End-User
    • 6.4.1. Hospitals
    • 6.4.2. Specialty Clinics
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 7.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Adults
    • 7.2.2. Pediatrics
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Neuroendocrine Tumors
    • 7.3.2. Prostate Cancer
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By End-User
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Clinics
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 8.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Adults
    • 8.2.2. Pediatrics
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Neuroendocrine Tumors
    • 8.3.2. Prostate Cancer
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By End-User
    • 8.4.1. Hospitals
    • 8.4.2. Specialty Clinics
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Rest of the World Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 9.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Adults
    • 9.2.2. Pediatrics
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Neuroendocrine Tumors
    • 9.3.2. Prostate Cancer
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By End-User
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Novartis AG
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Telix Pharmaceuticals Limited
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Ariceum Therapeutics
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Radiopharm Theranostics Limited
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Lantheus Holdings, Inc.
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Y-mAbs Therapeutics, Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. GLYTHERIX
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Curium
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 2: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 3: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 4: Global Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 5: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 7: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 8: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 9: North America Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 10: North America Lutetium-177 Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 12: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 13: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 14: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 15: Europe Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 17: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 18: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 20: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 22: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 23: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 24: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 25: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Lutetium-177 Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Lutetium-177 Market Value Share (%), by Drug, 2025 & 2034
  • Figure 3: Global Lutetium-177 Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 4: Global Lutetium-177 Market Value Share (%), by Application, 2025 & 2034
  • Figure 5: Global Lutetium-177 Market Value Share (%), by End-User, 2025 & 2034
  • Figure 6: North America Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 7: North America Lutetium-177 Market Value Share (%), by Drug, 2025
  • Figure 8: North America Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 9: North America Lutetium-177 Market Value Share (%), by Age Group, 2025
  • Figure 10: North America Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
  • Figure 11: North America Lutetium-177 Market Value Share (%), by Application, 2025
  • Figure 12: North America Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 13: North America Lutetium-177 Market Value Share (%), by End-User, 2025
  • Figure 14: North America Lutetium-177 Market Value (USD billion), By Country, 2025 & 2034
  • Figure 15: North America Lutetium-177 Market Value Share (%), By Country, 2025
  • Figure 16: Europe Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 17: Europe Lutetium-177 Market Value Share (%), by Drug, 2025
  • Figure 18: Europe Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 19: Europe Lutetium-177 Market Value Share (%), by Age Group, 2025
  • Figure 20: Europe Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
  • Figure 21: Europe Lutetium-177 Market Value Share (%), by Application, 2025
  • Figure 22: Europe Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 23: Europe Lutetium-177 Market Value Share (%), by End-User, 2025
  • Figure 24: Europe Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 25: Europe Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 26: Asia Pacific Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 27: Asia Pacific Lutetium-177 Market Value Share (%), by Drug, 2025
  • Figure 28: Asia Pacific Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 29: Asia Pacific Lutetium-177 Market Value Share (%), by Age Group, 2025
  • Figure 30: Asia Pacific Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
  • Figure 31: Asia Pacific Lutetium-177 Market Value Share (%), by Application, 2025
  • Figure 32: Asia Pacific Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 33: Asia Pacific Lutetium-177 Market Value Share (%), by End-User, 2025
  • Figure 34: Asia Pacific Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 35: Asia Pacific Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 36: Rest of the World Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 37: Rest of the World Lutetium-177 Market Value Share (%), by Drug, 2025
  • Figure 38: Rest of the World Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 39: Rest of the World Lutetium-177 Market Value Share (%), by Age Group, 2025
  • Figure 40: Rest of the World Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
  • Figure 41: Rest of the World Lutetium-177 Market Value Share (%), by Application, 2025
  • Figure 42: Rest of the World Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 43: Rest of the World Lutetium-177 Market Value Share (%), by End-User, 2025
  • Figure 44: Rest of the World Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Rest of the World Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2025

Figure 46: Global Lutetium-177 Market Share (%), By Company, 2025